Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in Houston, Texas and currently employs 44 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
AIMD stock price ended at $1.9 on 金曜日, after dropping 1.55%
On the latest trading day Jan 16, 2026, the stock price of AIMD fell by 1.55%, dropping from $1.95 to $1.90. During the session, the stock saw a volatility of 4.21%, with prices oscillating between a daily low of $1.90 and a high of $1.98. On the latest trading day, the trading volume for AIMD decreased by 2.7K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 7.3K shares were traded, with a market value of approximately $9.1M.